ClinicalTrials.gov
public full text
Public Domain
CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
This is an open-label, single-arm study to treat the adult R/R Large B-cell Lymphoma subjects with Relmacabtagene autoleucel (relma-cel) in China.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Anti-CD19-CAR-T Cells in Subjects With Relapsed/Refractory B Cell Malignancies#1095388
- CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma#834525
- CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas#349945
- CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies#1184744
- A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies#897975
Record · ID 1261364
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive